Combined Anticancer Therapy for Prostate Cancer - Literature Review
Authors:
- Patryk LasekPLPatryk Lasek
- Klaudia KowalczykKKKlaudia Kowalczyk
- Natalia TrąbkaNTNatalia Trąbka
- Nina LasotaNLNina Lasota
- Maciej SmerdzyńskiMSMaciej Smerdzyński
- Katarzyna ŁachKŁKatarzyna Łach
- Kinga ŚciurkaKŚKinga Ściurka
- Gabriela DemidowiczGDGabriela Demidowicz
- Kinga PanuciakKPKinga Panuciak
- Karolina KozickaKKKarolina Kozicka
Open Access
- 15 February 2024
- journal article
- review article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 60, 104-117
Abstract
Prostate cancers represent a significant health problem, and their etiology is complex and multifaceted. It is estimated that in 2018, 1.3 million new cases and 359,000 deaths due to prostate cancer were diagnosed. They constitute the second most common group of cancers and the fifth most common cause of cancer-related deaths in men worldwide. The present study encompasses a literature review aimed at conducting an analysis of the potential of combined anticancer therapy as a prospective method for enhancing treatment efficacy, minimizing side effects, and improving long-term survival outcomes for prostate cancer patients. Combinations of compounds such as sunitinib with docetaxel, carboplatin with paclitaxel, estramustine or flutamide with luteinizing hormone-releasing hormone agonists, as well as docetaxel in conjunction with dexamethasone and octreotide, have demonstrated synergistic effects and an augmentation of therapeutic effectiveness. It is noteworthy to emphasize the potential enhancement of docetaxel's anticancer activity with concurrent administration of dexamethasone and octreotide, as well as combined therapy involving docetaxel, prednisone, and curcumin.Keywords
This publication has 33 references indexed in Scilit:
- Cancer incidence in agricultural workers: Findings from an international consortium of agricultural cohort studies (AGRICOH)Environment International, 2021
- Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical StudiesHepatology, 2020
- Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate CancerClinical Genitourinary Cancer, 2019
- Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing GuidelinesJAMA Oncology, 2019
- Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinoneCancer, 2019
- Familial Risk and Heritability of Cancer Among Twins in Nordic CountriesJAMA, 2016
- Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenograftsCancer Letters, 2008
- Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancerJournal of Cancer Research and Clinical Oncology, 2007
- Mechanism of action and pure antiandrogenic properties of flutamideCancer, 1993
- Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndromeThe Lancet, 1990